About Zura Bio
Zura Bio is a clinical-stage biotechnology company developing therapies for immune and inflammatory diseases. Our mission is to advance biologic medicines that address the underlying drivers of disease and to improve outcomes for people living with conditions where treatment options remain limited.
Focus on Systemic Sclerosis (SSc)
Systemic sclerosis (SSc), also known as scleroderma, is a rare autoimmune disease marked by immune system overactivity, blood vessel injury, and scarring (fibrosis) of the skin and internal organs. People with SSc may face skin thickening, breathing difficulties, joint stiffness, gastrointestinal symptoms, and other complications that significantly affect quality of life.
Although progress has been made in rheumatology, a need remains to directly address the fibrotic process that drives SSc. Zura Bio is committed to exploring new approaches that focus on patients with SSc.
About Tibulizumab
Tibulizumab is Zura Bio’s investigational bispecific antibody designed to target two pathways involved in autoimmune and inflammatory disease:
Interleukin-17 (IL-17): a cytokine that contributes to inflammation and tissue scarring.
B-cell activating factor (BAFF): a protein that supports B-cell survival and is linked to persistent autoimmunity.
By targeting both IL-17 and BAFF, tibulizumab may offer a dual-pathway approach for complex conditions such as systemic sclerosis and hidradenitis suppurativa (HS).
Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by any regulatory agency worldwide.
The TibuSURE Phase 2 Clinical Trial in Systemic Sclerosis
Zura Bio is conducting the TibuSURE Phase 2 clinical trial to evaluate tibulizumab in adults with SSc.
ClinicalTrials.gov Identifier: NCT06843239
Design: Randomized, placebo-controlled Phase 2 clinical trial.
Objectives: Assess safety, tolerability, and explore signals of clinical activity.
Endpoints: Include measures of skin thickening and organ involvement.
Tibulizumab in Hidradenitis Suppurativa (HS)
Tibulizumab is also being evaluated in a separate Phase 2 clinical trial in adults with moderate-to-severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition that causes painful nodules and abscesses.
Our Commitment
At Zura Bio, we believe advancing science should also advance hope for patients. We are proud to attend the American College of Rheumatology and to collaborate with clinicians, researchers, and patient advocates working toward new solutions in autoimmune and inflammatory diseases.
For more information, please visit www.zurabio.com.